Document is current
Any future updates will be listed below
-
Authors
Barbanti, Piero https://orcid.org/0000-0002-5670-3755
Egeo, Gabriella
Aurilia, Cinzia
Fiorentini, Giulia
Proietti, Stefania
Tomino, Carlo
Bonassi, Stefano
,
Albanese, Maria
Allais, Giovanni
Altamura, Claudia
Aguggia, Marco
Autunno, Massimo
Balsamo, Patrizia
Bartoli, Marco
Bloise, Maria
Benedetto, Chiara
Bono, Francesco
Caggia, Giovanni
Camarda, Cecilia
Carnevale, Antonio
Cerchi, Alessandra
Cevoli, Sabina
Colombo, Bruno
Coppola, Alfonso
De Simone, Roberto
Di Clemente, Laura
Di Fiore, Paola
Di Summa, Alfonsina
d’Onofrio, Florindo
Favoni, Valentina
Filippi, Massimo
Finocchi, Cinzia
Frediani, Fabio
Grazzi, Licia
Grugno, Rosario
Mancioli, Andrea
Messina, Roberta
Messina, Stefano
Moschiano, Franca
Mostardini, Claudio
Paolucci, Matteo
Perini, Francesco
Pierangeli, Giulia
Querzani, Pietro
Rao, Renata
Rinalduzzi, Steno
Russo, Marco
Stochino, Erminia
Strumia, Silvia
Torelli, Paola
Valguerra, Fabio
Vernieri, Fabrizio
Viticchi, Giovanna
Zucco, Maurizio
-
Funding
Funding for this research was provided by:
IRCCS San Raffaele Pisana (Institutional Funding Ricerca Corrente)
- License Information
-
More Information
Article History
Received: 6 June 2022
Accepted: 10 June 2022
First Online: 8 July 2022
Declarations
:
: “None” (Mandatory)
: Piero Barbanti received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Alder, Allergan, Angelini, Assosalute, Bayer, electroCore, Eli Lilly, GSK, Lundbeck, Lusofarmaco, 1MED, MSD, New Penta, Noema Pharma, Novartis, STX-Med, Teva, Visufarma, and Zambon. Cinzia Aurilia received travel grants from FB-Health, Lusofarmaco, Almirall, Eli Lilly, Novartis, and Teva. Gabriella Egeo received travel grants and honoraria from Eli Lilly, Novartis, New Penta, and Ecupharma. Giulia Fiorentini has no disclosures to declare. S. Proietti has no disclosures to declare. C. Tomino has no disclosures to declare. S. Bonassi has no disclosures to declare.
